



“My spasticity makes it harder to take my medication”

LYVISPAH is a rapidly dissolvable formulation of baclofen.¹

Baclofen. Now dissolvable.

Indication

- LYVISPAH™ (baclofen) oral granules is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
- LYVISPAH may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Limitations of Use:

LYVISPAH is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.


Please see additional Important Safety Information throughout and enclosed Full Prescribing Information.

 **LYVISPAH™**
(baclofen) oral granules

Baclofen is now available in a dissolvable form

LYVISPAH™ provides the clinical benefits of baclofen in a convenient, rapidly dissolvable granule formulation¹

- Baclofen has been well established for the treatment of spasticity²
- LYVISPAH is bioequivalent to oral baclofen tablets^{1,3}



IMPORTANT SAFETY INFORMATION (continued)

Contraindication

LYVISPAH is contraindicated in patients with hypersensitivity to baclofen.

Warnings and Precautions

- Abrupt discontinuation of baclofen, regardless of the cause, has resulted in adverse reactions that include hallucinations, seizures, high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death. Therefore, reduce the dosage slowly when LYVISPAH is discontinued, unless the clinical situation justifies a rapid withdrawal.

Please see additional Important Safety Information throughout and enclosed Full Prescribing Information.

Customized dosing for individual patient needs

LYVISPAH provides flexible dosing as it comes in 5 mg, 10 mg, and 20 mg single-dose packets of flavored granules⁴

- **Rapidly dissolving** strawberry-flavored granules provide an **alternative** for patients with spasticity who also have **difficulty swallowing pills¹**
- **Conveniently stored** at room temperature providing an added benefit to patients **on-the-go⁴**
- **Samples** are available in the **5 mg and 10 mg** dosage strengths



Commercially insured patients may pay as little as \$10 for their prescription*

*Up to maximum benefit of \$100. Subject to eligibility. Individual out-of-pocket costs may vary. Not valid for patients covered under Medicare, Medicaid, or other federal or state programs. Please see full Terms, Conditions and Eligibility Criteria at LyvispahHCP.com/savings.

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

- Neonatal withdrawal can occur; gradually reduce the dosage and discontinue LYVISPAH before delivery.
- LYVISPAH can cause drowsiness and sedation. Patients should avoid the operation of automobiles or other dangerous machinery until they know how the drug affects them. Advise patients that the central nervous system effects of LYVISPAH may be additive to those of alcohol and other CNS depressants.
- LYVISPAH can cause exacerbation of the following: psychotic disorders, schizophrenia, or confusional states; autonomic dysreflexia; epilepsy. Use with caution in patients with these conditions.
- LYVISPAH should be used with caution in patients who have had a stroke.

LYVISPAH™
(baclofen) oral granules

Baclofen.
Now dissolvable. 3



Flexibility of administration

LYVISPAH can be administered in 3 ways⁴



1. Poured directly into the patient's mouth, with or without water



2. Mixed with liquids or soft foods, such as apple sauce, yogurt, or pudding*



3. Via enteral feeding tube[†]

Visit LyvispahHCP.com/admin or scan the QR code to view a short video detailing the 3 modes of administration



*Must be taken within 2 hours.

[†]Feeding tubes may become blocked when medications that are not specifically indicated for enteral administration are used. LYVISPAH is the only oral baclofen FDA approved for both oral and enteral feeding-tube administration.

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions

- The most common adverse reactions (>1%) in patients treated with baclofen for spasticity are drowsiness, dizziness, weakness, nausea, confusion, hypotension, headache, insomnia, constipation, urinary frequency, and fatigue.

Drug Interactions

- LYVISPAH can cause CNS depression, including drowsiness and sedation, which may be an additive when used concomitantly with other CNS depressants or alcohol.

Please see additional Important Safety Information throughout and enclosed Full Prescribing Information.



BlinkRx makes prescribing LYVISPAH simple

E-Prescribe LYVISPAH to "BlinkRx U.S. Boise, Idaho"

- You can also prescribe by **phone (833-984-2820)** or **fax (866-585-4631)**
- BlinkRx saves your patients time with free home delivery and automatically applies eligible savings, including co-pay support



No forms to fill out—your e-Rx provides all that's needed




No special portal required for patients



No software required or doctor portal to visit



BlinkRx provides prior authorization support and conducts benefits investigations



Patients may receive a 30-day free trial of LYVISPAH exclusively through BlinkRx

LYVISPAH is also available at retail pharmacies.

IMPORTANT SAFETY INFORMATION (continued)

Use in Specific Populations

- Pregnancy: There are no adequate data on the developmental risks associated with the use of LYVISPAH in pregnant women. LYVISPAH should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Baclofen.
Now dissolvable. 5

LYVISPAH. Clinical benefits of baclofen. Rapidly dissolvable.



LYVISPAH is bioequivalent to oral baclofen tablets^{1,3}

- Available in **5 mg, 10 mg, and 20 mg** single-dose packets
- **Administered 3 ways:** directly from packet, mixed with liquid or soft food, or via an enteral feeding tube
- Prescribe via **BlinkRx**, which helps with everything from **prior authorization to co-pay support**
- Eligible patients may **pay as little as \$10** for their prescription*

Samples available for your patients to start LYVISPAH today

*Up to maximum benefit of \$100. Subject to eligibility. Individual out-of-pocket costs may vary. Not valid for patients covered under Medicare, Medicaid, or other federal or state programs. Please see full Terms, Conditions and Eligibility Criteria at LyvispahHCP.com/savings.

IMPORTANT SAFETY INFORMATION *(continued)*

Use in Specific Populations *(continued)*

- Lactation: Nursing mothers should exercise caution, as oral baclofen has been shown to pass into milk at therapeutic doses. Withdrawal symptoms can occur in breastfed infants when maternal administration of LYVISPAH is stopped, or when breastfeeding is stopped.
- Pediatrics: Safety and effectiveness in pediatric patients below the age of 12 have not been established.
- Elderly Patients: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease of other drug therapy.
- Renal Impairment: Because baclofen is primarily excreted unchanged through the kidneys, LYVISPAH should be given with caution to patients with renal impairment, and it may be necessary to reduce the dosage.

Please see additional Important Safety Information throughout and enclosed Full Prescribing Information.

References: **1.** Office of Clinical Pharmacology Review (Lyvispah®). NDA number 215422. Link to EDR: \\CDSESUB1\evsprod\NDA215422\0001. Submission date 1/22/2021. Submission type: Original NDA (505(b)(2)). **2.** Ghanavatian S, Derian A. Baclofen. [Updated 2022 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526037/> **3.** Data on file [Amneal]. **4.** LYVISPAH (baclofen) oral granules [Prescribing Information]. Roswell, GA: Saol Therapeutics; 2021.



LYVISPAH™ is a trademark owned by Amneal Pharmaceuticals LLC.
Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
© 2023 Amneal Pharmaceuticals LLC. All rights reserved.
Printed in USA. PP-HCP-LYVI-US-0017 03/2023

LYVISPAH™
(baclofen) oral granules

Baclofen. Now dissolvable.